Use of insurance claims data to assess outpatient antimicrobial therapy for gram-positive infections

Area of Science:

• Infectious Diseases
• Health Economics
• Pharmacoeconomics

Background:

• Rising prevalence of antibiotic-resistant gram-positive infections necessitates increased outpatient treatment.
• Current cost-assessment methods for outpatient antimicrobial therapy are often resource-intensive and yield small sample sizes.
• Insurance claims data present a feasible alternative for large-scale cost analyses.

Purpose of the Study:

• To evaluate the utility of insurance claims data for analyzing outpatient antimicrobial therapy costs.
• To determine the cost of intravenous vancomycin home care for gram-positive infections.

Main Methods:

• Retrospective analysis of insurance claims data from a large insurance provider.
• Focus on patients receiving home care for gram-positive infections treated with intravenous vancomycin.

Main Results:

• Insurance claims data offer a convenient and potentially more efficient method for cost studies.
• Specific cost data for vancomycin home care were obtained.

Conclusions:

• Insurance claims data are a valuable resource for understanding the economic burden of outpatient antimicrobial therapy.
• This methodology can support healthcare policy and resource allocation for managing infectious diseases.